New stock news | Haina Pharmaceuticals' Hong Kong stock IPO prospectus invalidated.
The Hong Kong stock prospectus submitted by Nanjing Haina Pharmaceutical Technology Co., Ltd. (referred to as Haina Pharmaceutical) on November 7, 2025, will expire on May 7, 2026, after being valid for 6 months.
Nanjing Haina Pharmaceutical Technology Co., Ltd. (referred to as Haina Medicine) submitted its Hong Kong IPO prospectus on November 7, 2025, which expired on May 7, 2026, six months after submission, with CICC as its exclusive sponsor at the time of submission.
According to the previous prospectus, Haina Medicine is an integrated pharmaceutical research and manufacturing company that provides CXO services; at the same time, the company has a proprietary product pipeline that is mainly commercialized through pharmaceutical technology transfer. According to a Frost & Sullivan report, during the historical performance period and up to the last practicable date (November 2, 2025), Haina Medicine ranked second among CXO service providers in China engaged in drug technology transfer, in terms of the total number of approved clinical trials and market approvals. According to the same source, Haina Medicine also ranked second in terms of the total number of clinical trial and market approval applications submitted during the same period.
Related Articles
The return of the lithium king! America's Albemarle Corporation (ALB.US) follows the sharp rise in lithium prices, with Q1 profits surpassing expectations.
Arm(ARM.US) stock price after Q4 earnings report "roller coaster": The chill in the mobile market remains, AI data centers becoming a growth lifeline, in-house chips facing production bottlenecks.
Zhongtai: The better-than-expected catalyst of the first quarter report of science and technology, the logic of mapping technology between China and the United States will be further strengthened. It is recommended to firmly embrace the technology main line.
The return of the lithium king! America's Albemarle Corporation (ALB.US) follows the sharp rise in lithium prices, with Q1 profits surpassing expectations.
Arm(ARM.US) stock price after Q4 earnings report "roller coaster": The chill in the mobile market remains, AI data centers becoming a growth lifeline, in-house chips facing production bottlenecks.
Zhongtai: The better-than-expected catalyst of the first quarter report of science and technology, the logic of mapping technology between China and the United States will be further strengthened. It is recommended to firmly embrace the technology main line.
